Impact BioMedical, Inc.

Day range

$3.10 – $3.74

Open

$3.74

Prev close

$3.60

Volume

3.23K

Market cap

$30.76M

Shares out

8.54M

P/E

38.98

P/S

878.78

P/B

2.86

P/FCF

—

ROE

7.3%

ROA

4.7%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Charter amendmentOct 9, 2026

  On September 23, 2026, the Company filed a Certificate of Amendment ... with the Secretary of State of the State of Nevada to effect a one-for-twelve point six two (1-for-12.62) reverse stock split.

• Stock splitSep 15, 2026

  The Reverse Stock Split will become effective at 12:01 a.m., Eastern Time, on September 23, 2026. As a result of the Reverse Stock Split, every 12.62 shares of the Company's issued and outstanding common stock will be automatically combined and converted into one share of common stock.

• Acquisition consideration sharesMar 4, 2026

  The Amendment clarifies that the Impact Compensation Shares and the DSS Shares will be deducted from the Company Share Consideration to be issued to the Dr Ashleys Shareholder at Closing. Accordingly, the definition of "Company Share Consideration" was amended to provide that PubCo shall issue 169,560,000 PubCo ordinary shares, representing 94.20% of the total issued and outstanding PubCo ordinary shares at the Closing.

• Annual meeting resultsNov 6, 2025

  On November 5, 2025, Impact Biomedical Inc. (the "Company") held its 2025 annual meeting of stockholders (the "Annual Meeting"). A total of 64,328,010 shares of common stock of the Company, representing 88.50% of the aggregate shares outstanding and eligible to vote on September 8, 2025, the record date for the Meeting, and constituting a quorum, were represented in person or by valid proxies at the Meeting. The stockholders approved the election of Frank D. Heuszel; Elise Brownell; Melissa Sims; Castel Hibbert; David Keene; Christian Zimmerman; Jason Grady and Chan Heng Fai Ambrose to serve as directors of the Company until the next Annual Meeting of the shareholders.

• Warrant or conversionOct 27, 2025

  DSS BioHealth Security, Inc. has elected to convert the Series A Convertible Preferred Stock into shares of common stock, $0.001 par value per share (the "Common Stock") of the Company. Section 6 of the Certificate of Designation provides for an Optional Conversion on behalf of the holder at any time seventy-five (75) days after the issuance into one share of the Company's Common Stock. DSS BioHealth Security, Inc. shall be deemed the record holder of the 60,496,041 shares of Common Stock that are issuable pursuant to the aforementioned conversion.

Days to cover

2.0

Short interest

30.17K

Avg volume

15.21K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• ImPact Biotech Reports Encouraging Early Clinical Results From Phase 1 Study of Padeliporfin VTP in Pancreatic Cancer, with Seven Previously Unresectable Patients Undergoing Surgical Resection Following Treatment
  positiveGlobeNewswire Inc.· Oct 23, 2026
• CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
  neutralGlobeNewswire Inc.· Sep 14, 2026
• ImPact Biotech Presents Updated Data from Phase 1 Trial of Padeliporfin VTP in LA-PDAC and Phase 3 ENLIGHTED Trial in LG-UTUC at ASCO 2026
  positiveGlobeNewswire Inc.· May 30, 2026
• ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026
  positiveGlobeNewswire Inc.· May 16, 2026
• Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
  negativeGlobeNewswire Inc.· Apr 3, 2026